高级检索
当前位置: 首页 > 详情页

Antibacterial and DNA-Based Hydrogels in Situ Block TNF-α to Promote Diabetic Alveolar Bone Rebuilding

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism Research, West China Hospital, Sichuan University, Chengdu, 610041, China. [2]Department of Dermatology, West China Hospital, Sichuan University, Chengdu, 610041, China. [3]Animal Experimental Center, West China Hospital, Sichuan University, Chengdu, 610041, China. [4]Core facility of West China Hospital, Sichuan University, Chengdu, 610041, China. [5]WestChina-California Research Center for Predictive Intervention Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China. [6]Centre for Transplant and Renal Research, Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, 2145, Australia.
出处:
ISSN:

关键词: silver nanocluster DNA hydrogel tumor necrosis factor-alpha alveolar bone antibacterial

摘要:
Alveolar bone injury under diabetic conditions can severely impede many oral disease treatments. Rebuilding diabetic alveolar bone in clinics is currently challenging due to persistent infection and inflammatory response. Here, we develop an antibacterial DNA-based hydrogel named Agantigel by integrating silver nanoclusters (AgNCs) and tumor necrosis factor-alpha (TNF-α) antibody into DNA hydrogel to promote diabetic alveolar bone regeneration. Agantigel can effectively inhibit bacterial growth through AgNCs while exhibiting negligible cytotoxicity in vitro. The sustained release of TNF-α antibody from Agantigel effectively blocks TNF-α and promotes M2 polarization of macrophages, ultimately accelerating diabetic alveolar bone regeneration in vivo. After 21 days of treatment, Agantigel significantly accelerates the defect healing rate of diabetic alveolar bone up to 82.58 ± 8.58% and improves trabecular architectures compared to free TNF-α (42.52 ± 15.85%). Our results imply that DNA hydrogels are potential bio-scaffolds helping the sustained release of multidrug for treating DABI or other oral diseases. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 3 区 化学
小类 | 3 区 高分子科学
最新[2023]版:
大类 | 3 区 化学
小类 | 3 区 高分子科学
第一作者:
第一作者机构: [1]Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism Research, West China Hospital, Sichuan University, Chengdu, 610041, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43390 今日访问量:1 总访问量:3121 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号